LUMIFY PRESERVATIVE FREE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUMIFY PRESERVATIVE FREE (LUMIFY PRESERVATIVE FREE).
Selective alpha-1 adrenergic receptor agonist; causes vasoconstriction of conjunctival blood vessels, reducing redness.
| Metabolism | Not extensively metabolized; systemic absorption minimal. |
| Excretion | Primarily renal excretion of unchanged drug (approx. 60-80%) and metabolites (glucuronide conjugates). Biliary/fecal elimination accounts for <10%. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours. Clinical context: Allows for twice-daily dosing for sustained intraocular pressure reduction; steady-state achieved within 2 days. |
| Protein binding | Approximately 60-70% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Vd is approximately 0.5-1.0 L/kg, indicating distribution into total body water; higher Vd suggests extensive tissue binding. |
| Bioavailability | Topical ocular: Systemic absorption is minimal (<1% of administered dose) due to extensive presystemic metabolism and low corneal permeability; oral bioavailability is not clinically relevant. |
| Onset of Action | Ocular topical: Onset of intraocular pressure reduction within 1-2 hours; peak effect at 2-4 hours. |
| Duration of Action | Duration of intraocular pressure reduction is up to 24 hours with twice-daily dosing; clinically effective for at least 12 hours after a single dose. |
1 drop in each affected eye every 6-8 hours as needed, ophthalmic route.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients; use not recommended. |
| Geriatric use | No specific dosage adjustment required; use with caution due to potential increased systemic absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUMIFY PRESERVATIVE FREE (LUMIFY PRESERVATIVE FREE).
| Breastfeeding | Brimonidine is excreted in human milk following oral administration; however, the extent of excretion after ocular administration is unknown. Limited data suggest that brimonidine may suppress lactation. Caution should be exercised; consider alternative treatments. M/P ratio not established. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal studies, brimonidine (the active ingredient) showed no teratogenic effects at oral doses up to 2.5 mg/kg/day (approximately 100 times the human ocular dose). Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: no known specific risk. Second and third trimesters: avoid due to potential for maternal hypotension and reduced uteroplacental perfusion. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to brimonidine or any component; narrow-angle glaucoma; patients with cardiovascular disease or hypertension should use caution.
| Precautions | Do not use with narrow-angle glaucoma; discontinue if eye pain, vision changes, or continued redness occur; overuse may cause rebound redness. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate due to potential systemic effects (hypotension, bradycardia). Monitor fetal heart rate and uterine activity in third trimester if used near term. |
| Fertility Effects | No human data on fertility effects. In animal studies, oral brimonidine at high doses (2.5 mg/kg/day) caused decreased fertility in female rats. Reversible effects on male fertility (reduced sperm count) observed at higher doses. Relevance to human ocular use is unknown. |